StockData
Mesoblast Ltd logo

Mesoblast Ltd (MESO) stock

MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30
$11.64−0.27 (-2.27%)

Close on Nov 18, 2026Market cap $1.51BP/E –Yield –

Mesoblast revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Mesoblast's revenue for the twelve months ending Jun 30, 2023 was $7.50M, down 26.5% year over year. For fiscal 2026 it was $120.25M, up 599.2% from the year before. Over ten years it grew 10.9% a year on average. The highest annual figure on record is $120.25M in fiscal 2026.

Annual revenue

PeriodPeriod endValueChange
FY2026Jun 30, 2026$120.25M+599.2%
FY2025Jun 30, 2025$17.20M+191.4%
FY2024Jun 30, 2024$5.90M-21.3%
FY2023Jun 30, 2023$7.50M-26.5%
FY2022Jun 30, 2022$10.21M+37.4%
FY2021Jun 30, 2021$7.43M-76.9%
FY2020Jun 30, 2020$32.16M+92.3%
FY2019Jun 30, 2019$16.72M-3.6%
FY2018Jun 30, 2018$17.34M+618.9%
FY2017Jun 30, 2017$2.41M-94.3%
FY2016Jun 30, 2016$42.55M–

Quarterly revenue

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q4 FY2023CQ2 2023Jun 30, 2023$2.14M-3.8%
Q3 FY2023CQ1 2023Mar 31, 2023$1.94M-3.6%
Q2 FY2023CQ4 2022Dec 31, 2022$2.13M-10.4%
Q1 FY2023CQ3 2022Sep 30, 2022$1.50M-58.2%
Q4 FY2022CQ2 2022Jun 30, 2022$2.22M+12.7%
Q3 FY2022CQ1 2022Mar 31, 2022$2.01M+5.0%
Q2 FY2022CQ4 2021Dec 31, 2021$2.38M+6.3%
Q1 FY2022CQ3 2021Sep 30, 2021$3.59M+175.4%
Q4 FY2021CQ2 2021Jun 30, 2021$1.97M+181.5%
Q3 FY2021CQ1 2021Mar 31, 2021$1.92M-84.3%
Q2 FY2021CQ4 2020Dec 31, 2020$2.24M+1.6%
Q1 FY2021CQ3 2020Sep 30, 2020$1.31M-92.3%
Q4 FY2020CQ2 2020Jun 30, 2020$701.00K-64.4%
Q3 FY2020CQ1 2020Mar 31, 2020$12.20M+876.9%
Q2 FY2020CQ4 2019Dec 31, 2019$2.21M+18.0%
Q1 FY2020CQ3 2019Sep 30, 2019$17.05M+46.5%
Q4 FY2019CQ2 2019Jun 30, 2019$1.97M+15.7%
Q3 FY2019CQ1 2019Mar 31, 2019$1.25M+16.7%
Q2 FY2019CQ4 2018Dec 31, 2018$1.87M-86.0%
Q1 FY2019CQ3 2018Sep 30, 2018$11.64M–
Q4 FY2018CQ2 2018Jun 30, 2018$1.70M–
Q3 FY2018CQ1 2018Mar 31, 2018$1.07M–
Q2 FY2018CQ4 2017Dec 31, 2017$13.40M–

More Mesoblast figures

See a number that looks wrong?